The introduction of blood donor screening by virus nucleic acid amplification technology (NAT) in the mid to late 1990s was driven by the so-called AIDS and hepatitis C virus (HCV) epidemic, with thousands of recipients of infected blood products and components. Plasma fractionators were the first to introduce NAT testing besides pathogen reduction procedures, to reduce the virus transmission risk through their products. To achieve a similar safety standard, NAT was then also introduced for labile blood components. German transfusion centres were the first to start in-house NAT testing of their donations in pools of up to 96 samples for HCV, hepatitis B virus (HBV), and human immunodeficiency virus-1 (HIV-1). Years later the diagnostics industry provided commercial HCV and HIV-1 and later HBV NAT tests on automated platforms. NAT tests for HIV-2, hepatitis A virus, and Parvovirus B19 followed, again driven by transfusion centres with their in-house tests. When severe acute respiratory syndrome corona virus (SARS-CoV) and West Nile Virus emerged it was the NAT that enabled the manufacturers and transfusion centres to instantly introduce sensitive and specific screening tests. Subsequent automation including sample preparation has significantly reduced the costs and complexity of the procedure and made it affordable to middle income countries as well. Currently more than 60 million donations per year are NAT tested worldwide and the remaining residual risk of virus transmission by blood components and products could be reduced to almost zero. Automation rendered possible the reduction of pool size in conjunction with increased throughput and sensitivity. Thus, antibody and antigen testing may be dispensable in the long run, particularly in the combination of NAT testing with pathogen reduction. There are new technologies on the horizon like digital droplet PCR, next-generation sequencing, lab-on-a-chip, and digital antigen assays, which are comparably sensitive. However, each of these has limitations, either in throughput, costs, automation, time to result, specificity, or the need for NAT as an integral part of the technology. Thus, NAT is still the shortest and most efficient means to the result. Donor screening NAT also contributed significantly to our knowledge on how fast viruses replicate, and on the respective diagnostic window. In conjunction with animal and patient studies, we have learned more about the minimal infectious dose and the epidemics in the donor population.

1.
Saiki
RK
,
Scharf
S
,
Faloona
F
,
Mullis
KB
,
Horn
GT
,
Erlich
HA
, et al.
Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia
.
Science
.
1985
Dec
;
230
(
4732
):
1350
4
.
[PubMed]
0036-8075
2.
Higuchi
R
,
Dollinger
G
,
Walsh
PS
,
Griffith
R
.
Simultaneous amplification and detection of specific DNA sequences
.
Biotechnology (N Y)
.
1992
Apr
;
10
(
4
):
413
7
.
[PubMed]
0733-222X
3.
Gottlieb
MS
,
Schroff
R
,
Schanker
HM
,
Weisman
JD
,
Fan
PT
,
Wolf
RA
, et al.
Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency
.
N Engl J Med
.
1981
Dec
;
305
(
24
):
1425
31
.
[PubMed]
0028-4793
4.
Update on acquired immune deficiency syndrome (AIDS) among patients with haemophilia A. MMWR Weekly, December 10, 1982 / 31(48); 644-652.
5.
Epidemiologic Notes and Reports Possible Transfusion-Associated Acquired Immune Deficiency Syndrome (AIDS) – California. MMWR Weekly, December 10, 1982 / 31(48);652-4.
6.
Kuo
G
,
Choo
QL
,
Alter
HJ
,
Gitnick
GL
,
Redeker
AG
,
Purcell
RH
, et al.
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis
.
Science
.
1989
Apr
;
244
(
4902
):
362
4
.
[PubMed]
0036-8075
7.
Esteban
JI
,
González
A
,
Hernández
JM
,
Viladomiu
L
,
Sánchez
C
,
López-Talavera
JC
, et al.
Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis
.
N Engl J Med
.
1990
Oct
;
323
(
16
):
1107
12
.
[PubMed]
0028-4793
8.
Schramm
W
,
Roggendorf
M
,
Rommel
F
,
Kammerer
R
,
Pohlmann
H
,
Rasshofer
R
, et al.
Prevalence of antibodies to hepatitis C virus (HCV) in haemophiliacs
.
Blut
.
1989
Oct
;
59
(
4
):
390
2
.
[PubMed]
0006-5242
9.
Makris
M
,
Preston
FE
,
Triger
DR
,
Underwood
JC
,
Choo
QL
,
Kuo
G
, et al.
Hepatitis C antibody and chronic liver disease in haemophilia
.
Lancet
.
1990
May
;
335
(
8698
):
1117
9
.
[PubMed]
0140-6736
10.
Kubanek
B
,
Cardoso
M
,
Glück
D
,
Koerner
K
.
[Risk of infection transmission by blood components]
.
Infusionsther Transfusionsmed
.
1993
Apr
;
20
(
1-2
):
54
9
.
[PubMed]
1019-8466
11.
Sibrowski
W
,
Penner
M
,
Kühnl
P
.
[Transfusion-induced virus infections: how great is the risk?]
.
Infusionsther Transfusionsmed
.
1993
Jun
;
20
Suppl 2
:
4
9
.
[PubMed]
1019-8466
12.
Der Spiegel 41/
1993
13.
Deutscher Bundestag 12. Wahlperiode (Hrsg): Zweite Beschlussempfehlung und Schlussbericht des 3. Untersuchungsausschusses nach Artikel 44 des Grundgesetzes. Drucksache 12/8591. 25.10.94
14.
Wikipedia
:
Infektionen durch HIV-kontaminierte Blutprodukte
15.
Centers for Disease Control and Prevention (CDC)
. MMWR Morb Mortal Wkly Rep. 1994 Jul 22;43(28):505-9. Outbreak of hepatitis C associated with intravenous immunoglobulin administration--United States, October 1993-June
1994
.
16.
Yap
PL
,
McOmish
F
,
Webster
AD
,
Hammarstrom
L
,
Smith
CI
,
Bjorkander
J
, et al.
Hepatitis C virus transmission by intravenous immunoglobulin
.
J Hepatol
.
1994
Sep
;
21
(
3
):
455
60
.
[PubMed]
0168-8278
17.
Bjøro
K
,
Frøland
SS
,
Yun
Z
,
Samdal
HH
,
Haaland
T
.
Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin
.
N Engl J Med
.
1994
Dec
;
331
(
24
):
1607
11
.
[PubMed]
0028-4793
18.
Makris
M
,
Garson
JA
,
Ring
CJ
,
Tuke
PW
,
Tedder
RS
,
Preston
FE
.
Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients
.
Blood
.
1993
Apr
;
81
(
7
):
1898
902
.
[PubMed]
0006-4971
19.
CPMP/BWP/390/97: Note for Guidance on the Introduction of Nucleic Acid Amplification Technology (NAT) for the Detection of Hepatitis C Virus RNA in Plasma Pools.
20.
Saldanha
J
,
Minor
P
.
A sensitive PCR method for detecting HCV RNA in plasma pools, blood products, and single donations
.
J Med Virol
.
1994
May
;
43
(
1
):
72
6
.
[PubMed]
0146-6615
21.
Wolff
C
,
Hörnschemeyer
D
,
Skurtopulos
M
,
Petersen
N
,
Beyer
J
,
Seidel
K
, et al.
[Molecular biological screening of viruses important to transfusion medicine]
.
Beitr Infusionsther Transfusionsmed
.
1994
;
32
:
102
9
.
[PubMed]
1023-2028
22.
Schottstedt
V
,
Tuma
W
,
Bünger
G
,
Lefèvre
H
.
PCR for HBV, HCV and HIV-1 experiences and first results from a routine screening programme in a large blood transfusion service
.
Biologicals
.
1998
Jun
;
26
(
2
):
101
4
.
[PubMed]
1045-1056
23.
Cardoso
MS
,
Koerner
K
,
Kubanek
B
.
Mini-pool screening by nucleic acid testing for hepatitis B virus, hepatitis C virus, and HIV: preliminary results
.
Transfusion
.
1998
Oct
;
38
(
10
):
905
7
.
[PubMed]
0041-1132
24.
Roth
WK
,
Weber
M
,
Seifried
E
.
Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting
.
Lancet
.
1999
Jan
;
353
(
9150
):
359
63
.
[PubMed]
0140-6736
25.
Bundesanzeiger
Nr
. 53 vom 18. März
1998
, S. 3835
26.
Sun
R
,
Schilling
W
,
Jayakar
H
,
Ku
J
,
Wang
J
,
Rosenstraus
M
, et al.
Simultaneous extraction of hepatitis C virus (HCV), hepatitis B virus, and HIV-1 from plasma and detection of HCV RNA by a reverse transcriptase-polymerase chain reaction assay designed for screening pooled units of donated blood
.
Transfusion
.
1999
Oct
;
39
(
10
):
1111
9
.
[PubMed]
0041-1132
27.
Drosten
C
,
Seifried
E
,
Roth
WK
.
TaqMan 5′-nuclease human immunodeficiency virus type 1 PCR assay with phage-packaged competitive internal control for high-throughput blood donor screening
.
J Clin Microbiol
.
2001
Dec
;
39
(
12
):
4302
8
.
[PubMed]
0095-1137
28.
Hennig
H
,
Luhm
J
,
Hartwig
D
,
Klüter
H
,
Kirchner
H
.
A novel RT-PCR for reliable and rapid HCV RNA screening of blood donations
.
Transfusion
.
2001
Sep
;
41
(
9
):
1100
6
.
[PubMed]
0041-1132
29.
Baylis
SA
,
Wallace
P
,
McCulloch
E
,
Niesters
HG
,
Nübling
CM
.
Standardization of nucleic acids tests: the approach of the World Health Organization
.
J Clin Microbiol
.
2019
Jan
;
57
(
1
):
e01056
18
.
[PubMed]
1098-660X
30.
Hourfar
MK
,
Jork
C
,
Schottstedt
V
,
Weber-Schehl
M
,
Brixner
V
,
Busch
MP
, et al.;
German Red Cross NAT Study Group
.
Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus
.
Transfusion
.
2008
Aug
;
48
(
8
):
1558
66
.
[PubMed]
0041-1132
31.
Zou
S
,
Dorsey
KA
,
Notari
EP
,
Foster
GA
,
Krysztof
DE
,
Musavi
F
, et al.
Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing
.
Transfusion
.
2010
Jul
;
50
(
7
):
1495
504
.
[PubMed]
0041-1132
32.
Roth
WK
,
Busch
MP
,
Schuller
A
,
Ismay
S
,
Cheng
A
,
Seed
CR
, et al.
International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009
.
Vox Sang
.
2012
Jan
;
102
(
1
):
82
90
.
[PubMed]
0042-9007
33.
Nübling
CM
,
Heiden
M
,
Chudy
M
,
Kress
J
,
Seitz
R
,
Keller-Stanislawski
B
, et al.
Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions
.
Transfusion
.
2009
Sep
;
49
(
9
):
1850
8
.
[PubMed]
0041-1132
34.
Schmidt
M
,
Korn
K
,
Nübling
CM
,
Chudy
M
,
Kress
J
,
Horst
HA
, et al.
First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany
.
Transfusion
.
2009
Sep
;
49
(
9
):
1836
44
.
[PubMed]
0041-1132
35.
Chudy
M
,
Kress
J
,
Halbauer
J
,
Heiden
M
,
Funk
MB
,
Nübling
CM
.
Risk Minimization Measures for Blood Screening HIV-1 Nucleic Acid Amplification Technique Assays in Germany
.
Transfus Med Hemother
.
2014
Feb
;
41
(
1
):
45
51
.
[PubMed]
1660-3796
36.
Bundesanzeiger BAnz AT 12.09.
2012
B6
37.
Zolt
SD
,
Thermann
R
,
Bangsow
T
,
Pichl
L
,
Müller
B
,
Jork
C
, et al.
Implementation of an HIV-1 Triple-Target NAT Assay in the Routine Screening at Three German Red Cross Blood Centres
.
Transfus Med Hemother
.
2016
May
;
43
(
3
):
183
9
.
[PubMed]
1660-3796
38.
Busch
MP
,
Caglioti
S
,
Robertson
EF
,
McAuley
JD
,
Tobler
LH
,
Kamel
H
, et al.
Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing
.
N Engl J Med
.
2005
Aug
;
353
(
5
):
460
7
.
[PubMed]
0028-4793
39.
Lai
L
,
Lee
TH
,
Tobler
L
,
Wen
L
,
Shi
P
,
Alexander
J
, et al.
Relative distribution of West Nile virus RNA in blood compartments: implications for blood donor nucleic acid amplification technology screening
.
Transfusion
.
2012
Feb
;
52
(
2
):
447
54
.
[PubMed]
0041-1132
40.
Berger
A
,
Drosten
C
,
Doerr
HW
,
Stürmer
M
,
Preiser
W
.
Severe acute respiratory syndrome (SARS)—paradigm of an emerging viral infection
.
[Review]
.
J Clin Virol
.
2004
Jan
;
29
(
1
):
13
22
.
[PubMed]
1386-6532
41.
Schmidt
M
,
Brixner
V
,
Ruster
B
,
Hourfar
MK
,
Drosten
C
,
Preiser
W
, et al.
NAT screening of blood donors for severe acute respiratory syndrome coronavirus can potentially prevent transfusion associated transmissions
.
Transfusion
.
2004
Apr
;
44
(
4
):
470
5
.
[PubMed]
0041-1132
42.
Abwehr von Arzneimittelrisiken
. Stufenplan Stufe 2: Anhörung zur Einführung Risiko- minimierender Maßnahmen zur Prävention von Übertragungen des Hepatitis-E-Virus durch Blutkomponenten zur Transfusion und von Stammzellzubereitungen zur hämatopoetischen Rekonstitution. 4.Juni
2018
.
43.
Dreier
J
,
Knabbe
C
,
Vollmer
T.
Transfusion-Transmitted Hepatitis E: NAT Screening of Blood Donations and Infectious Dose. Front Med (Lausanne).
2018
Feb 1;5:5. doi: . eCollection 2018.
44.
Domanović
D
,
Tedder
R
,
Blümel
J
,
Zaaijer
H
,
Gallian
P
,
Niederhauser
C
, et al.
Hepatitis E and blood donation safety in selected European countries: a shift to screening?
Euro Surveill
.
2017
Apr
;
22
(
16
):
30514
.
[PubMed]
1025-496X
45.
Busch
MP
.
Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients
.
Transfus Clin Biol
.
2001
Jun
;
8
(
3
):
200
6
.
[PubMed]
1246-7820
46.
Nübling
CM
,
Unger
G
,
Chudy
M
,
Raia
S
,
Löwer
J
.
Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase
.
Transfusion
.
2002
Aug
;
42
(
8
):
1037
45
.
[PubMed]
0041-1132
47.
Glynn
SA
,
Wright
DJ
,
Kleinman
SH
,
Hirschkorn
D
,
Tu
Y
,
Heldebrant
C
, et al.
Dynamics of viremia in early hepatitis C virus infection
.
Transfusion
.
2005
Jun
;
45
(
6
):
994
1002
.
[PubMed]
0041-1132
48.
Fiebig
EW
,
Wright
DJ
,
Rawal
BD
,
Garrett
PE
,
Schumacher
RT
,
Peddada
L
, et al.
Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection
.
AIDS
.
2003
Sep
;
17
(
13
):
1871
9
.
[PubMed]
0269-9370
49.
Kleinman
SH
,
Lelie
N
,
Busch
MP
.
Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion
.
Transfusion
.
2009
Nov
;
49
(
11
):
2454
89
.
[PubMed]
0041-1132
50.
Delwart
EL
,
Kalmin
ND
,
Jones
TS
,
Ladd
DJ
,
Foley
B
,
Tobler
LH
, et al.
First report of human immunodeficiency virus transmission via an RNA-screened blood donation
.
Vox Sang
.
2004
Apr
;
86
(
3
):
171
7
.
[PubMed]
0042-9007
51.
Tabuchi
A
,
Tanaka
J
,
Katayama
K
,
Mizui
M
,
Matsukura
H
,
Yugi
H
, et al.
Titration of hepatitis B virus infectivity in the sera of pre-acute and late acute phases of HBV infection: transmission experiments to chimeric mice with human liver repopulated hepatocytes
.
J Med Virol
.
2008
Dec
;
80
(
12
):
2064
8
.
[PubMed]
0146-6615
52.
Komiya
Y
,
Katayama
K
,
Yugi
H
,
Mizui
M
,
Matsukura
H
,
Tomoguri
T
, et al.
Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C
.
Transfusion
.
2008
Feb
;
48
(
2
):
286
94
.
[PubMed]
0041-1132
53.
Katayama
K
,
Kumagai
J
,
Komiya
Y
,
Mizui
M
,
Yugi
H
,
Kishimoto
S
, et al.
Titration of hepatitis C virus in chimpanzees for determining the copy number required for transmission
.
Intervirology
.
2004
;
47
(
1
):
57
64
.
[PubMed]
0300-5526
54.
Yoshikawa
A
,
Gotanda
Y
,
Minegishi
K
,
Taira
R
,
Hino
S
,
Tadokoro
K
, et al.;
Japanese Red Cross NAT Screening Research Group
.
Lengths of hepatitis B viremia and antigenemia in blood donors: preliminary evidence of occult (hepatitis B surface antigen-negative) infection in the acute stage
.
Transfusion
.
2007
Jul
;
47
(
7
):
1162
71
.
[PubMed]
0041-1132
55.
Roth
WK
,
Weber
M
,
Petersen
D
,
Drosten
C
,
Buhr
S
,
Sireis
W
, et al.
NAT for HBV and anti-HBc testing increase blood safety
.
Transfusion
.
2002
Jul
;
42
(
7
):
869
75
.
[PubMed]
0041-1132
56.
Passaes
CP
,
Bruel
T
,
Decalf
J
,
David
A
,
Angin
M
,
Monceaux
V
, et al.;
ANRS RHIVIERA Consortium
.
Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents
.
J Virol
.
2017
Feb
;
91
(
6
):
e02296
16
.
[PubMed]
0022-538X
57.
Schmidt
M
,
Hourfar
MK
,
Sireis
W
,
Pfeiffer
U
,
Göttig
S
,
Kempf
VA
, et al.
Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion-transmitted bacterial strains
.
Transfusion
.
2015
Sep
;
55
(
9
):
2104
12
.
[PubMed]
0041-1132
58.
Montag
T
,
Nicol
SB
,
Schurig
U
,
Heiden
M
,
Huber
H
,
Sanzenbacher
R
, et al.
Microbial safety of cell based medicinal products—what can we learn from cellular blood components?
[Review]
.
Clin Chem Lab Med
.
2008
;
46
(
7
):
963
5
.
[PubMed]
1434-6621
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.